<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475797</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0013</org_study_id>
    <nct_id>NCT03475797</nct_id>
  </id_info>
  <brief_title>Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias</brief_title>
  <acronym>StimO</acronym>
  <official_title>Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias: a Multicentric, Controlled, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medically intractable pain caused by occipital neuralgia can be very difficult to control
      with traditional pain management. Peripheral nerve stimulation which is used in migraines and
      cluster headache can be an alternative for these patients with occipital neuralgias when
      medical treatment and traditional pain management have failed (drugs for neuropathic pain,
      infiltrations, psychobehavioral approaches and multidisciplinary approach in a pain center).
      Occipital nerve stimulation consists to put a lead subcutaneously in front of the occipital
      nerve and to connect the lead to a pulse generator. A retrospective study of 60 patients was
      conducted in Nantes University Hospital. The results were good with the Visual Analog Scale
      (VAS) decreased from 8.4 preoperatively to 2.85 postoperatively. The medical quantification
      scale (MQS) was reduced to about 50% (18 preoperatively versus 9.9 postoperatively).
      Stimulation was quiet stable over time with a mean follow-up of 24 months (range 6 to 72
      months). The aim of StimO is to confirm this result through a national controlled randomized
      multicenter study where occipital nerve stimulation will be compared to the optimal medical
      management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of occipital nerve stimulation</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the decrease of pain (evaluated by visual analogic scale) after 6 months of treatment between the 2 groups (ONS / OMM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 3 months of occipital nerve stimulation in the ONS group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 6 months of occipital nerve stimulation in the ONS group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum pain (using Visual Analogic Scale)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of maximum pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain (using Visual Analogic Scale)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of average pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative decrease of pain (using Visual Analogic Scale) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of the relative decrease of pain (using Visual Analogic Scale) at 3 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative decrease of pain (using Visual Analogic Scale) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the relative decrease of pain (using Visual Analogic Scale) at 6 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (using EQ-5D-5L questionnaire)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of the quality of life (using EQ-5D-5L questionnaire) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (using Hamilton Anxiety and Depression (HAD) scale)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of the quality of life (using Hamilton Anxiety and Depression (HAD) scale) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Occipital Neuralgia</condition>
  <arm_group>
    <arm_group_label>Occipital Nerve Stimulation (ONS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Management (OMM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical Management according to what is done in routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occipital nerve stimulation</intervention_name>
    <description>Occipital nerve stimulation with percutaneous or surgical lead</description>
    <arm_group_label>Occipital Nerve Stimulation (ONS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Management</intervention_name>
    <description>Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.</description>
    <arm_group_label>Occipital Nerve Stimulation (ONS)</arm_group_label>
    <arm_group_label>Optimal Medical Management (OMM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 85 years old

          -  Chronic occipital neuralgias as defined by International Headache Society (IHS) more
             than 6 months with permanent pain associated or not with paroxysm

          -  Secondary occipital neuralgias (post-traumatic, post-surgery, major arthrosis,
             compression or lesion of the occipital nerve …)

          -  Chronic neuropathic pain according to the Neuropathic Pain Diagnostic Questionnaire
             (DN4 ≥ 4)

          -  Maximum pain on VAS ≥ 50/100

          -  Failure of medical treatment (association of neuropathic medication like antiepileptic
             and/or antidepressant and/or antalgic treatment like paracetamol, tramadol or
             morphine) and pain management in a pain Unit including multidisciplinary approach,
             physiotherapy, block test in C1-C2, radiofrequency rhizolysis, and/or corticosteroid
             infiltration of C2 according to the criteria defined by Health Authorities for spinal
             cord stimulation.

          -  Reduction of pain with Transcutaneous Electrical Nerve Stimulation (TENS) in occipital
             area

          -  Neurological examen has to be completed and must be normal except for the occipital
             neuralgia territory

          -  A negative pregnancy test for women with childbearing potential

          -  Women of childbearing potential must use appropriate method(s) of contraception during
             the clinical trial

          -  Patients must be capable of giving informed consent and must have signed informed
             consent

          -  Affiliation to an appropriate health insurance

        Exclusion Criteria:

          -  Contraindication to the experimental medical devices

          -  Titanium related allergies

          -  Patients with contraindications to general anesthesia

          -  Complete anaesthesia in the C2/Great occipital nerve territory

          -  Drug or alcohol addiction

          -  Psychiatric disorders (psychiatric evaluation)

          -  Any medical or psychological problems which may interfere with a smooth conduction of
             the study protocol (e.g. cancer with a limited life expectancy)

          -  Need for intensive nursing care

          -  Difficulty in follow-up

          -  Pregnant or lactating women

          -  Women not using contraception

          -  Adults under a legal protection regime (guardianship, trusteeship, &quot;sauvegarde de
             justice&quot;)

          -  Exclusion period for another study

          -  Simultaneous participation in another clinical trial except if that other trial does
             not affect the StimO study as approved and documented by the sponsor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvie RAOUL, MD, PhD</last_name>
    <phone>(+33) (0)2 40 16 50 80</phone>
    <email>sylvie.raoul@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evelyne Emery, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marie-Françoise Amiel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Jacques Lemaire, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Xavier Moisset, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jimmy Voirin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Richard Schalck, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Mertens, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jean-Bernard Caillet, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Raoul, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Julien Nizard, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denys Fontaine, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michel Lantéri-Minet, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nouman Aldahak, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alain Serrie, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Paris</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Béchir Jarraya, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marie-Christine Djian-Hallepee, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Rigoard, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elodie Charrier, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

